Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) — Tangible Net Worth Ratio
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a Tangible Net Worth Ratio of 95.9% as of March 2026. This metric is calculated by deducting intangible assets (€307.19 Million) from net assets (€7.52 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 2TZ working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Tangible Net Worth Ratio (2013–2025)
This chart shows how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 95.9%, reflecting net assets of €7.52 Billion with intangible assets of €307.19 Million EUR. See Tianjin Zhong Xin Pharmaceutical Group C (2TZ) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Tianjin Zhong Xin Pharmaceutical Group C (2TZ) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 95.6% | €7.10 Billion | €311.15 Million | €11.69 Billion | ▼ -0.1 pp |
| 2024 | 95.7% | €7.85 Billion | €337.62 Million | €10.77 Billion | ▲ +0.7 pp |
| 2023 | 95.0% | €6.65 Billion | €330.83 Million | €10.23 Billion | ▼ -0.5 pp |
| 2022 | 95.5% | €6.55 Billion | €292.13 Million | €10.16 Billion | ▼ -1.3 pp |
| 2021 | 96.9% | €6.51 Billion | €202.91 Million | €9.07 Billion | ▲ +0.3 pp |
| 2020 | 96.6% | €5.95 Billion | €204.02 Million | €8.28 Billion | ▼ -0.3 pp |
| 2019 | 96.8% | €5.52 Billion | €175.57 Million | €7.84 Billion | ▲ +0.3 pp |
| 2018 | 96.5% | €5.05 Billion | €174.86 Million | €7.11 Billion | ▲ +0.4 pp |
| 2017 | 96.1% | €4.63 Billion | €179.33 Million | €6.62 Billion | ▲ +0.3 pp |
| 2016 | 95.8% | €4.30 Billion | €178.63 Million | €6.36 Billion | ▲ +0.4 pp |
| 2015 | 95.5% | €4.11 Billion | €185.60 Million | €6.07 Billion | ▲ +2.0 pp |
| 2014 | 93.5% | €2.95 Billion | €191.02 Million | €5.44 Billion | ▲ +1.2 pp |
| 2013 | 92.3% | €2.57 Billion | €197.06 Million | €5.26 Billion | — |